611 related articles for article (PubMed ID: 20709811)
1. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
Mashima T; Okabe S; Seimiya H
Mol Pharmacol; 2010 Nov; 78(5):846-54. PubMed ID: 20709811
[TBL] [Abstract][Full Text] [Related]
2. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.
Yan J; Xie B; Capodice JL; Katz AE
Prostate; 2012 Feb; 72(3):244-52. PubMed ID: 21656835
[TBL] [Abstract][Full Text] [Related]
3. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
Sadar MD; Gleave ME
Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779
[TBL] [Abstract][Full Text] [Related]
4. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression.
Cheng H; Snoek R; Ghaidi F; Cox ME; Rennie PS
Cancer Res; 2006 Nov; 66(21):10613-20. PubMed ID: 17079486
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines.
Pignon JC; Koopmansch B; Nolens G; Delacroix L; Waltregny D; Winkler R
Cancer Res; 2009 Apr; 69(7):2941-9. PubMed ID: 19318561
[TBL] [Abstract][Full Text] [Related]
6. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
7. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Ishii N; Aoki Y
Prostate; 2010 Apr; 70(5):457-66. PubMed ID: 19902465
[TBL] [Abstract][Full Text] [Related]
8. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
Jackson KM; Frazier MC; Harris WB
Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
[TBL] [Abstract][Full Text] [Related]
9. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
10. Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line.
Wang LG; Ossowski L; Ferrari AC
Cancer Res; 2001 Oct; 61(20):7544-51. PubMed ID: 11606392
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor effect of small interfering RNA targeting the androgen receptor in human androgen-independent prostate cancer cells.
Azuma K; Nakashiro K; Sasaki T; Goda H; Onodera J; Tanji N; Yokoyama M; Hamakawa H
Biochem Biophys Res Commun; 2010 Jan; 391(1):1075-9. PubMed ID: 20004643
[TBL] [Abstract][Full Text] [Related]
12. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
13. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M; Latham DE; Delaney MA; Chakravarti A
Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
Seaton A; Scullin P; Maxwell PJ; Wilson C; Pettigrew J; Gallagher R; O'Sullivan JM; Johnston PG; Waugh DJ
Carcinogenesis; 2008 Jun; 29(6):1148-56. PubMed ID: 18487223
[TBL] [Abstract][Full Text] [Related]
15. Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth.
Minamiguchi K; Kawada M; Ohba S; Takamoto K; Ishizuka M
Mol Cell Endocrinol; 2004 Feb; 214(1-2):175-87. PubMed ID: 15062556
[TBL] [Abstract][Full Text] [Related]
16. Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells.
Lim JT; Piazza GA; Pamukcu R; Thompson WJ; Weinstein IB
Clin Cancer Res; 2003 Oct; 9(13):4972-82. PubMed ID: 14581372
[TBL] [Abstract][Full Text] [Related]
17. 20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.
Fousteris MA; Schubert U; Roell D; Roediger J; Bailis N; Nikolaropoulos SS; Baniahmad A; Giannis A
Bioorg Med Chem; 2010 Oct; 18(19):6960-9. PubMed ID: 20826091
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
Zaia A; Fraizer GC; Piantanelli L; Saunders GF
Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
[TBL] [Abstract][Full Text] [Related]
19. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.
Snoek R; Cheng H; Margiotti K; Wafa LA; Wong CA; Wong EC; Fazli L; Nelson CC; Gleave ME; Rennie PS
Clin Cancer Res; 2009 Jan; 15(1):39-47. PubMed ID: 19118031
[TBL] [Abstract][Full Text] [Related]
20. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.
Hsieh CL; Cai C; Giwa A; Bivins A; Chen SY; Sabry D; Govardhan K; Shemshedini L
J Mol Endocrinol; 2008 Jul; 41(1):13-23. PubMed ID: 18469090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
